EP 0722937 A1 19960724 - 2,8-Disubstituted quinazolinone
Title (en)
2,8-Disubstituted quinazolinone
Title (de)
2,8-Disubstituierte Chinazolinone
Title (fr)
Quinazolinones disubstituées en 2,8
Publication
Application
Priority
DE 19501481 A 19950119
Abstract (en)
2,8-Disubstd. quinazolinones of formula (I) and their tautomers and salts are new: A = oxiranyl opt. substd. by 1-8C alkyl or phenyl (1-8C) alkyl; -C(R1)=CHR2; -CH(R3)LR4; or -CH2R5; R1 = H or 1-6C alkyl; R2 = 1-8C alkyl or phenyl (1-8C) alkyl; R3 = 1-5C alkyl or OR6; R6 = H, a protecting gp. or 1-5C alkyl; R4 = 2-10C alkyl or phenyl (2-10C) alkyl; L = CO, CHOH, CH2 or CHOSO2R7; R7 = 1-4C alkyl or phenyl; R5 = 3-8C alkyl, phenyl (3-8C) alkyl, benzyl or 2-phenylethyl; D = H or SO2NR8R9; R8 and R9 = H, phenyl, 1-6C alkyl or 1-6C hydroxyalkyl, or NR8R9 is a 5- or 6-membered satd. ring which contains 0-2 further heteroatoms (S, N and/or O) and is opt. substd. via free N function by 1-6C alkyl or hydroxyalkyl; E = 1-8C alkyl.
Abstract (de)
2,8-Disubstituierte Chinazolinone werden hergestellt, indem man zunächst durch übliche Reaktionen das Chinazolinongrundgerüst kondensiert und anschließend den gewünschten Substituenten in 8-Position einführt. Die Verbindungen eignen sich als Wirkstoffe in Arzneimitteln, insbesondere zur Behandlung von Entzündungen, thromboembolischen Erkrankungen sowie Herz-/Kreislauferkrankungen.
IPC 1-7
IPC 8 full level
A61K 31/505 (2006.01); A61K 31/517 (2006.01); A61K 31/535 (2006.01); A61K 31/655 (2006.01); A61P 7/02 (2006.01); A61P 9/06 (2006.01); A61P 9/08 (2006.01); A61P 9/10 (2006.01); A61P 13/08 (2006.01); A61P 29/00 (2006.01); A61P 43/00 (2006.01); C07D 239/91 (2006.01); C07D 405/04 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01)
CPC (source: EP KR US)
A61K 31/505 (2013.01 - KR); A61P 7/02 (2018.01 - EP); A61P 9/00 (2018.01 - EP); A61P 9/06 (2018.01 - EP); A61P 9/08 (2018.01 - EP); A61P 9/10 (2018.01 - EP); A61P 13/08 (2018.01 - EP); A61P 29/00 (2018.01 - EP); A61P 43/00 (2018.01 - EP); C07D 239/91 (2013.01 - EP US); C07D 239/92 (2013.01 - KR); C07D 405/04 (2013.01 - EP KR US)
Citation (search report)
[DX] WO 9312095 A1 19930624 - PFIZER LTD [GB], et al
Designated contracting state (EPC)
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
EP 0722937 A1 19960724; AR 006738 A1 19990929; AU 4098096 A 19960725; AU 704102 B2 19990415; BG 100293 A 19960731; BR 9600148 A 19980106; CA 2167345 A1 19960720; CN 1134417 A 19961030; CO 4700522 A1 19981229; CZ 16796 A3 19960814; DE 19501481 A1 19960725; EE 9600019 A 19960815; FI 960227 A0 19960117; FI 960227 A 19960720; HR P960004 A2 19980228; HU 9600114 D0 19960328; HU P9600114 A2 19961230; HU P9600114 A3 20000328; IL 116770 A0 19960514; IL 116770 A 20000831; IN 184956 B 20001007; JP H08253457 A 19961001; KR 960029325 A 19960817; MA 23780 A1 19961001; NO 307513 B1 20000417; NO 960222 D0 19960118; NO 960222 L 19960722; NZ 280831 A 19961028; PE 66696 A1 19970309; PL 312352 A1 19960722; RO 117451 B1 20020329; RU 2158733 C2 20001110; SG 34377 A1 19961206; SK 7796 A3 19960807; SV 1996000005 A 19970311; TR 199600029 A2 19960821; US 5721238 A 19980224; YU 1496 A 19980918; ZA 96397 B 19960828
DOCDB simple family (application)
EP 96100154 A 19960108; AR 10108796 A 19960119; AU 4098096 A 19960115; BG 10029396 A 19960118; BR 9600148 A 19960118; CA 2167345 A 19960116; CN 96101906 A 19960119; CO 96002168 A 19960119; CZ 16796 A 19960118; DE 19501481 A 19950119; EE 9600019 A 19960118; FI 960227 A 19960117; HR P960004 A 19960105; HU P9600114 A 19960119; IL 11677096 A 19960116; IN 2408DE1995 A 19951226; JP 2297396 A 19960117; KR 19960001004 A 19960118; MA 24135 A 19960118; NO 960222 A 19960118; NZ 28083196 A 19960116; PE 00004496 A 19960119; PL 31235296 A 19960117; RO 9600077 A 19960116; RU 96100854 A 19960118; SG 1996000263 A 19960117; SK 7796 A 19960118; SV 1996000005 A 19960119; TR 9600029 A 19960115; US 58486596 A 19960111; YU 1496 A 19960112; ZA 96397 A 19960118